TN2013000256A1 - Methods and drug products for treating alzheimer's disease - Google Patents
Methods and drug products for treating alzheimer's diseaseInfo
- Publication number
- TN2013000256A1 TN2013000256A1 TNP2013000256A TN2013000256A TN2013000256A1 TN 2013000256 A1 TN2013000256 A1 TN 2013000256A1 TN P2013000256 A TNP2013000256 A TN P2013000256A TN 2013000256 A TN2013000256 A TN 2013000256A TN 2013000256 A1 TN2013000256 A1 TN 2013000256A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- disease
- drug products
- alzheimer
- treating alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431370P | 2011-01-10 | 2011-01-10 | |
| PCT/US2012/020606 WO2012096873A1 (fr) | 2011-01-10 | 2012-01-09 | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000256A1 true TN2013000256A1 (en) | 2014-11-10 |
Family
ID=46491234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000256A TN2013000256A1 (en) | 2011-01-10 | 2013-06-14 | Methods and drug products for treating alzheimer's disease |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9102666B2 (fr) |
| EP (2) | EP3106165B1 (fr) |
| JP (4) | JP2014505055A (fr) |
| KR (2) | KR20180050420A (fr) |
| CN (2) | CN107362165A (fr) |
| AR (1) | AR084816A1 (fr) |
| AU (1) | AU2012205798B2 (fr) |
| BR (1) | BR112013017446A2 (fr) |
| CA (1) | CA2824050A1 (fr) |
| CL (1) | CL2013001947A1 (fr) |
| CO (1) | CO6741212A2 (fr) |
| CR (1) | CR20130377A (fr) |
| DO (1) | DOP2017000105A (fr) |
| EA (2) | EA201691399A1 (fr) |
| EC (1) | ECSP13012814A (fr) |
| GE (1) | GEP201706786B (fr) |
| HK (1) | HK1246660A1 (fr) |
| IL (2) | IL226975B (fr) |
| MA (1) | MA34828B1 (fr) |
| MX (2) | MX355479B (fr) |
| PE (2) | PE20140051A1 (fr) |
| SG (1) | SG191399A1 (fr) |
| TN (1) | TN2013000256A1 (fr) |
| TW (3) | TWI645853B (fr) |
| UA (1) | UA114704C2 (fr) |
| UY (1) | UY33863A (fr) |
| WO (1) | WO2012096873A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| EP2789695B1 (fr) * | 2008-08-12 | 2019-10-30 | Zinfandel Pharmaceuticals, Inc. | Traitement de la maladie d'Alzheimer des sujets identifiés en détectant la présence d'un variant génétique dans le gène TOMM40 en rs 1052423 |
| CN107362165A (zh) | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
| EA201490840A1 (ru) | 2011-10-21 | 2014-08-29 | Такеда Фармасьютикал Компани Лимитед | Препарат с замедленным высвобождением |
| WO2013106084A1 (fr) * | 2012-01-09 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer |
| EP2987489A4 (fr) * | 2013-04-19 | 2016-09-07 | Takeda Pharmaceutical | Formulation de médicament à libération contrôlée |
| EP3074525A4 (fr) * | 2013-11-26 | 2017-08-23 | University of North Texas Health Science Center at Fort Worth | Approche médicale personnalisée pour le traitement d'une perte cognitive |
| JP6566471B2 (ja) * | 2015-07-01 | 2019-08-28 | 国立大学法人福井大学 | 自閉スペクトラム症診断補助のための医療用画像処理方法及び医療用画像処理システム並びにバイオマーカー |
| CA2992616C (fr) | 2015-07-23 | 2023-01-03 | Asuragen, Inc. | Procedes, compositions, trousses, et utilisations pour l'analyse d'acides nucleiques comprenant des segments de repetition riches en a/t |
| WO2018119018A1 (fr) * | 2016-12-23 | 2018-06-28 | Genervon Biopharmaceuticals, LLC | Procédés d'utilisation de gm6 dans le diagnostic et le traitement de la maladie d'alzheimer |
| JP6161183B1 (ja) | 2017-02-14 | 2017-07-12 | 株式会社日本生物製剤 | 記憶改善用ペプチド |
| CA3037958C (fr) * | 2017-02-22 | 2022-06-14 | Jeffrey L. Sugarman | Glitazones pour application topique |
| US20200258629A1 (en) * | 2017-10-31 | 2020-08-13 | Ge Healthcare Limited | Medical system for diagnosing cognitive disease pathology and/or outcome |
| US10888225B2 (en) * | 2017-11-10 | 2021-01-12 | Weinberg Medical Physics Inc | Red blood cells as voltage-sensitive contrast agents |
| WO2019223880A1 (fr) * | 2018-05-25 | 2019-11-28 | Toyota Motor Europe | Système et procédé pour déterminer la charge perceptive et le niveau de perception de stimulus d'un cerveau humain |
| WO2019234664A1 (fr) | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyéthyl)pyridin-2-yl]éthoxy]phényl]méthyl]-1,3-thiazolidine-2,4-dione et ses sels destinés à être dans le traitement de maladies mitochondriales |
| CN110779566B (zh) * | 2018-07-13 | 2021-09-28 | 致伸科技股份有限公司 | 具有辅助判断功能的产品测试系统及产品测试辅助方法 |
| WO2020237203A1 (fr) * | 2019-05-23 | 2020-11-26 | Indiana University Research And Technology Corporation | Méthodes d'évaluation objective de la mémoire, détection précoce du risque de maladie d'alzheimer, mise en correspondance d'individus avec des traitements, surveillance de la réponse à un traitement, et nouvelles méthodes d'utilisation de médicaments |
| US10902351B1 (en) * | 2019-08-05 | 2021-01-26 | Kpn Innovations, Llc | Methods and systems for using artificial intelligence to analyze user activity data |
| CN112151113A (zh) * | 2020-09-27 | 2020-12-29 | 类承斌 | 一种迟发性阿尔茨海默症关联基因变异的早期筛查方法 |
| CN114452264B (zh) * | 2021-12-15 | 2023-09-05 | 东药集团沈阳施德药业有限公司 | 一种盐酸吡格列酮胶囊及其制备方法 |
| KR20230134755A (ko) | 2022-03-15 | 2023-09-22 | 사회복지법인 삼성생명공익재단 | 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법 |
| TWI822460B (zh) * | 2022-11-11 | 2023-11-11 | 國立陽明交通大學 | 罹患阿茲海默症之風險分析方法 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US6060237A (en) | 1985-02-26 | 2000-05-09 | Biostar, Inc. | Devices and methods for optical detection of nucleic acid hybridization |
| US5112460A (en) | 1986-10-21 | 1992-05-12 | Northeastern University | High performance microcapillary gel electrophoresis |
| EP0842925A1 (fr) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Thiazolidinédiones substituées |
| US5595883A (en) | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
| US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
| TW263504B (fr) | 1991-10-03 | 1995-11-21 | Pfizer | |
| US5326770A (en) | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
| IL106877A (en) | 1992-09-10 | 1998-03-10 | Lilly Co Eli | Rodinin derivatives for use as drugs for the treatment of Alzheimer's disease |
| NZ257215A (en) | 1992-10-13 | 1996-12-20 | Univ Duke | Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| US5904824A (en) | 1997-03-07 | 1999-05-18 | Beckman Instruments, Inc. | Microfluidic electrophoresis device |
| WO1998039967A1 (fr) | 1997-03-12 | 1998-09-17 | The General Hospital Corporation | Procede de traitement ou de prevention de la maladie d'alzheimer |
| ATE229004T1 (de) | 1997-03-31 | 2002-12-15 | Korea Res Inst Chem Tech | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung |
| DE69834508T2 (de) | 1997-11-19 | 2006-11-23 | Takeda Pharmaceutical Co. Ltd. | Apoptoseinhibitoren |
| US6964868B1 (en) | 1998-01-28 | 2005-11-15 | Nuvelo, Inc. | Human genes and gene expression products II |
| JP2002534055A (ja) | 1998-05-14 | 2002-10-15 | カイロン コーポレイション | ヒト遺伝子および遺伝子発現産物ｖ |
| AU771187B2 (en) | 1998-11-10 | 2004-03-18 | Genset | Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| CN1078616C (zh) | 1998-12-16 | 2002-01-30 | 中国科学院上海生命科学研究中心 | 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒 |
| JP2000273040A (ja) | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | トログリタゾンを含有するアポトーシス抑制剤 |
| US6401043B1 (en) | 1999-04-26 | 2002-06-04 | Variagenics, Inc. | Variance scanning method for identifying gene sequence variances |
| CA2371391A1 (fr) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone et metformine comme inhibiteurs de formation de produits terminaux de glycation avancee (age) |
| DE19936719A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
| US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| AR030920A1 (es) | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
| US6532467B1 (en) | 2000-04-10 | 2003-03-11 | Sas Institute Inc. | Method for selecting node variables in a binary decision tree structure |
| US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| AU2002211666A1 (en) | 2000-10-11 | 2002-04-22 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US20040122091A1 (en) | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| MXPA03003020A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de cetona y composiciones para el control del colesterol y usos relacionados. |
| WO2002030882A2 (fr) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Composes de sulfoxyde et de bis-sulfoxyde et compositions pour reguler le cholesterol, et applications associees |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CA2429817C (fr) | 2000-11-24 | 2013-02-12 | Vascular Biogenics Ltd. | Procedes faisant appels a des phospholipides oxydes definis, ainsi que compositions contenant ces derniers, pour la prevention et le traitement de l'atherosclerose |
| US6495335B2 (en) | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
| DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| US20040204502A1 (en) | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US20050020694A1 (en) | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US6828462B2 (en) | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| US7132244B2 (en) | 2001-11-21 | 2006-11-07 | Syn X Pharma, Inc. | Betaine/GABA transport protein biopolymer marker indicative of insulin resistance |
| US7052849B2 (en) | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
| US7135297B2 (en) | 2001-11-23 | 2006-11-14 | Nanogen Inc. | Protein biopolymer markers indicative of insulin resistance |
| US20030220374A1 (en) | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| WO2004005510A1 (fr) | 2002-07-05 | 2004-01-15 | Shionogi & Co., Ltd. | Nouveau polypeptide du type recepteur nogo et adn correspondant |
| US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
| AU2003291910B2 (en) | 2002-12-24 | 2009-10-01 | Bellus Health (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| CN101103969A (zh) | 2002-12-24 | 2008-01-16 | 神经化学（国际）有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
| CA2515783A1 (fr) | 2003-02-14 | 2004-09-02 | Intergenetics Incorporated | Identification statistique d'un risque accru de developper une maladie |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US20050004179A1 (en) | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
| US20070203083A1 (en) | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
| JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用 |
| US7944467B2 (en) | 2003-12-01 | 2011-05-17 | Omnivision Technologies, Inc. | Task-based imaging systems |
| CA2555367A1 (fr) | 2004-01-22 | 2005-08-11 | Genaissance Pharmaceuticals, Inc. | Marqueurs genetiques apoe associes a l'age de l'apparition de la maladie d'alzheimer |
| TW200538738A (en) | 2004-02-20 | 2005-12-01 | Univ California | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
| WO2006054297A2 (fr) | 2004-11-17 | 2006-05-26 | Compugen Ltd. | Nouvelles sequences nucleotidiques et d'acides amines, et leurs dosages et leurs procedes d'utilisation pour le diagnostic |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| US20060228728A1 (en) | 2005-01-31 | 2006-10-12 | Perlegen Sciences, Inc. | Genetic basis of Alzheimer's disease and diagnosis and treatment thereof |
| CA2620333A1 (fr) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
| EA200800879A1 (ru) * | 2005-09-22 | 2008-10-30 | ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
| WO2007044522A1 (fr) | 2005-10-05 | 2007-04-19 | Auburn University | P62 identifiee comme determinant du risque de developper le syndrome metabolique |
| ES2654908T3 (es) | 2006-03-16 | 2018-02-15 | Metabolic Solutions Development Company Llc | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica |
| US20080045582A1 (en) | 2006-05-15 | 2008-02-21 | Issam Zineh | ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools |
| EP2037948B1 (fr) | 2006-05-30 | 2016-04-13 | Mayo Foundation For Medical Education And Research | Detection et traitement de la demence |
| US7651840B2 (en) | 2006-07-14 | 2010-01-26 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
| CA2663347A1 (fr) | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Modulation induite par ppar de la neurogenese |
| US20090042849A1 (en) | 2006-12-06 | 2009-02-12 | Yochai Birnbaum | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof |
| US7794937B2 (en) | 2006-12-22 | 2010-09-14 | Quest Diagnostics Investments Incorporated | Cystic fibrosis transmembrane conductance regulator gene mutations |
| GB0702537D0 (en) | 2007-02-12 | 2007-03-21 | Leuven K U Res & Dev | Treatment for excessive adiposity |
| US20080286876A1 (en) | 2007-05-14 | 2008-11-20 | Chissoe Stephanie | GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip |
| WO2008147562A2 (fr) | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Formulations de régime et procédés de traitement d'une inflammation et d'autres troubles |
| TW200914006A (en) | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| EP2789695B1 (fr) | 2008-08-12 | 2019-10-30 | Zinfandel Pharmaceuticals, Inc. | Traitement de la maladie d'Alzheimer des sujets identifiés en détectant la présence d'un variant génétique dans le gène TOMM40 en rs 1052423 |
| US20100136584A1 (en) | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| CA2742324A1 (fr) | 2008-10-30 | 2010-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Procedes d'evaluation de motifs arn |
| WO2010056337A2 (fr) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Procédés et systèmes d'utilisation d'exosomes pour déterminer des phénotypes |
| CN102245581A (zh) | 2008-12-12 | 2011-11-16 | 普克塞尔公司 | 用于治疗与ampk活性有关的疾病的四氢三嗪化合物 |
| JP2012516842A (ja) | 2009-02-02 | 2012-07-26 | ライラ ニュートラシューティカルズ | 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 |
| EP3444611A1 (fr) | 2009-04-23 | 2019-02-20 | Siemens Healthcare Diagnostics Inc. | Formes monomères et dimères de fragments du récepteur de l'adiponectine et procédés d'utilisation |
| AU2010202926B2 (en) | 2009-09-11 | 2016-07-14 | Electrophoretics Limited | Markers and methods relating to the assessment of Alzheimer's disease |
| US20110194996A1 (en) | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Transport container for stabilized liquid samples |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| WO2011127219A1 (fr) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Biomarqueurs circulants pour une maladie |
| CN107362165A (zh) * | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
-
2012
- 2012-01-09 CN CN201710506942.0A patent/CN107362165A/zh active Pending
- 2012-01-09 MX MX2016002647A patent/MX355479B/es unknown
- 2012-01-09 MA MA36114A patent/MA34828B1/fr unknown
- 2012-01-09 CA CA2824050A patent/CA2824050A1/fr not_active Abandoned
- 2012-01-09 US US13/346,081 patent/US9102666B2/en not_active Expired - Fee Related
- 2012-01-09 WO PCT/US2012/020606 patent/WO2012096873A1/fr active Application Filing
- 2012-01-09 PE PE2013001527A patent/PE20140051A1/es not_active Application Discontinuation
- 2012-01-09 PE PE2018000334A patent/PE20181179A1/es unknown
- 2012-01-09 EP EP16174214.3A patent/EP3106165B1/fr active Active
- 2012-01-09 MX MX2013008067A patent/MX339844B/es active IP Right Grant
- 2012-01-09 EA EA201691399A patent/EA201691399A1/ru unknown
- 2012-01-09 JP JP2013548602A patent/JP2014505055A/ja active Pending
- 2012-01-09 UA UAA201309798A patent/UA114704C2/uk unknown
- 2012-01-09 EP EP12734726.8A patent/EP2665479B1/fr active Active
- 2012-01-09 GE GEAP201213185A patent/GEP201706786B/en unknown
- 2012-01-09 SG SG2013050166A patent/SG191399A1/en unknown
- 2012-01-09 EA EA201391017A patent/EA201391017A1/ru unknown
- 2012-01-09 AU AU2012205798A patent/AU2012205798B2/en not_active Ceased
- 2012-01-09 BR BR112013017446A patent/BR112013017446A2/pt not_active Application Discontinuation
- 2012-01-09 KR KR1020187011843A patent/KR20180050420A/ko active IP Right Grant
- 2012-01-09 KR KR1020137020591A patent/KR102171747B1/ko active IP Right Grant
- 2012-01-09 CN CN201280012588.1A patent/CN103501783A/zh active Pending
- 2012-01-10 UY UY0001033863A patent/UY33863A/es not_active Application Discontinuation
- 2012-01-10 TW TW106121990A patent/TWI645853B/zh not_active IP Right Cessation
- 2012-01-10 AR ARP120100073A patent/AR084816A1/es unknown
- 2012-01-10 TW TW101100913A patent/TWI595875B/zh not_active IP Right Cessation
- 2012-01-10 TW TW105123423A patent/TWI612139B/zh not_active IP Right Cessation
-
2013
- 2013-06-14 TN TNP2013000256A patent/TN2013000256A1/fr unknown
- 2013-06-16 IL IL226975A patent/IL226975B/en active IP Right Grant
- 2013-07-01 CL CL2013001947A patent/CL2013001947A1/es unknown
- 2013-08-05 CR CR20130377A patent/CR20130377A/es unknown
- 2013-08-06 CO CO13187439A patent/CO6741212A2/es unknown
- 2013-08-09 EC ECSP13012814 patent/ECSP13012814A/es unknown
-
2014
- 2014-03-27 HK HK18106193.2A patent/HK1246660A1/zh unknown
-
2015
- 2015-06-15 US US14/739,511 patent/US9724339B2/en active Active
-
2016
- 2016-10-25 JP JP2016208540A patent/JP2017014296A/ja active Pending
-
2017
- 2017-04-26 DO DO2017000105A patent/DOP2017000105A/es unknown
- 2017-05-22 US US15/600,833 patent/US20170319565A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158277A patent/JP6745304B2/ja active Active
-
2019
- 2019-01-28 US US16/259,134 patent/US11179375B2/en active Active
- 2019-03-04 IL IL265155A patent/IL265155A/en unknown
-
2020
- 2020-08-03 JP JP2020131817A patent/JP2020176142A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000256A1 (en) | Methods and drug products for treating alzheimer's disease | |
| WO2012174338A3 (fr) | Procédé de sélection d'indications thérapeutiques | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| MX2013005564A (es) | Medicamentos de canabinoides en bajas dosis. | |
| IN2015DN00376A (fr) | ||
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| IN2015DN00450A (fr) | ||
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| MX2014005209A (es) | Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas. | |
| IN2012DN06309A (fr) | ||
| WO2012145535A3 (fr) | Modèle animal de cancer humain et procédés pour son utilisation | |
| SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
| WO2012100043A3 (fr) | Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg | |
| WO2013109279A3 (fr) | Stabilisation de l'anticorps anti-cd20 rituximab | |
| MX2015005993A (es) | Composiciones y metodos para el tratamiento de displasia ectodermica. | |
| WO2014081709A3 (fr) | Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton | |
| WO2012153253A3 (fr) | Composés aromatiques et complexes métalliques de ceux-ci | |
| MX358594B (es) | Factores de riesgo de enfermedad y métodos de uso. | |
| WO2012040444A3 (fr) | Traitement de patients présentant un début de maladie d'alzheimer | |
| CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
| Mani et al. | Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation | |
| Moutton | Memory troubles and confusion: case report |